KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Eli Lilly (LLY) over the last 17 years, with Q3 2025 value amounting to $531.0 million.

  • Eli Lilly's Cash from Financing Activities rose 15130.15% to $531.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $440.4 million, marking a year-over-year decrease of 9119.24%. This contributed to the annual value of $1.2 billion for FY2024, which is 6481.0% down from last year.
  • According to the latest figures from Q3 2025, Eli Lilly's Cash from Financing Activities is $531.0 million, which was up 15130.15% from -$1.2 billion recorded in Q2 2025.
  • Eli Lilly's 5-year Cash from Financing Activities high stood at $3.5 billion for Q4 2023, and its period low was -$2.9 billion during Q1 2022.
  • In the last 5 years, Eli Lilly's Cash from Financing Activities had a median value of -$311.3 million in 2024 and averaged -$218.2 million.
  • Per our database at Business Quant, Eli Lilly's Cash from Financing Activities crashed by 109194.0% in 2021 and then surged by 54320.59% in 2025.
  • Eli Lilly's Cash from Financing Activities (Quarter) stood at -$1.5 billion in 2021, then rose by 25.23% to -$1.1 billion in 2022, then soared by 410.56% to $3.5 billion in 2023, then tumbled by 106.36% to -$225.4 million in 2024, then soared by 335.58% to $531.0 million in 2025.
  • Its Cash from Financing Activities stands at $531.0 million for Q3 2025, versus -$1.2 billion for Q2 2025 and $1.4 billion for Q1 2025.